Yuhan

Yuhan EBIT Margin

The EBIT Margin (Operating Margin) of Yuhan (000100.KS) as of Nov 2, 2026 is 10.51 %. In the previous year, EBIT Margin (Operating Margin) was 3.27 % — a change of 221.71% (higher).

EBIT Margin

10.51 %

YoY

221.71%

Last updated:

EBIT Margin (Operating Margin) of Yuhan is 2025 10.51 % . EBIT Margin (Operating Margin) of Yuhan was 2024 3.27 % . It decreases by 221.71% higher compared to the previous year.

For Yuhan, the operating (EBIT) margin of 10.5% is up versus 2.9% a few years ago.

The Yuhan EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
3.30 KRW
Jan 1, 2019
0.85 KRW
Jan 1, 2020
5.20 KRW
Jan 1, 2021
2.88 KRW
Jan 1, 2022
2.03 KRW
Jan 1, 2023
3.07 KRW
Jan 1, 2024
3.27 KRW
Jan 1, 2025
10.51 KRW
The Yuhan EBIT Margin history
YEAREBIT MarginYoY
10.51 %+221.71%
3.27 %+6.53%
3.07 %+51.22%
2.03 %-29.54%
2.88 %-44.64%
5.20 %+514.23%
0.85 %-74.34%
3.30 %-45.60%
6.07 %-18.06%
7.40 %-2.64%
7.60 %+4.01%
7.31 %+11,056.44%
0.07 %+47.07%
0.04 %-42.60%
0.08 %-37.67%
0.12 %-6.72%
0.13 %-1.66%
0.14 %-6.51%
0.15 %-7.23%
0.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yuhan Stock analysis

What does Yuhan do? The Yuhan Corporation is a South Korean conglomerate that was founded on September 1, 1926, under the name "Chosun Pharmaceutical Company". The company is headquartered in Seoul and employs more than 5,000 people worldwide. History: The Yuhan Corporation started as a small company with a single product, a fish oil-based ointment called "Yuksundo". The company worked hard to improve its products and expand its market, eventually expanding into other business areas such as the production of antibiotics and diabetes treatments. In the early 1950s, the company also ventured into the research and development of other pharmaceuticals. In 1962, Yuhan became a publicly traded company and received a variety of awards in the following years, including several Korean Industrial Awards. Since its inception, the company has remained committed to improving people's lives through innovation and science. Business model: The Yuhan Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of drugs and other health products. The company also makes investments in innovative technologies and healthcare startups. Over the years, Yuhan has expanded its business through partnerships with other companies and acquisitions of companies such as LGL Holdings and SillaJen Inc. The company also engages in international business relations, such as selling its products and medications in other countries. Divisions: The Yuhan Corporation has four main business divisions: Medical Research and Development, Drug Manufacturing, Biotechnology Product Development, and Health Product Production. The first division is coordinated by Yuhan Research & Development Co. Ltd, while drug manufacturing is done by Yuhan Manufacturing Co. Ltd. Biotechnology is done by Yuhan Biomedical Research Institute, and the health product segment is handled by Yuhan Healthcare. Products: Yuhan's products are diverse and include a wide range of drugs and health products. The company is involved in the production of antibiotics, analgesics, vein treatment agents, diabetes medications, cardiovascular drugs, and other pharmaceutical products. Other products also include cosmetics, oral care products, and dermatology drugs. Some of Yuhan's well-known products include the antibiotic Ceclor, a medication for the treatment of diabetes and metabolic disorders, as well as apple-based cosmetic products. All Yuhan products are manufactured according to strict quality standards and are known for their effectiveness and safety. Conclusion: The Yuhan Corporation has evolved into a diverse and innovative company focused on the production of drugs and health products. The company has a long history with many successes and has established itself as one of the major forces in the South Korean economy over the past decades. Yuhan's mission to create better healthcare remains as relevant today as it was at the time of its founding. Yuhan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yuhan stock

EBIT Margin (Operating Margin) of Yuhan is 10.51 % in 2025.

EBIT Margin (Operating Margin) of Yuhan changed from 3.27 % to 10.51 %, representing a 221.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Yuhan since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Yuhan with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Yuhan

All Key Metrics — Yuhan